Recent Quotes (30 days)

You have no recent quotes
chg | %

GlaxoSmithKline plc news

   Watch this stock
Showing stories 21 - 30 of about 185   

Articles published

GSK 1,651.00 +8.50 (0.52%)
price chart
Novartis, Glaxo in deal to transform firms, industry
London/Mumbai: Novartis AG agreed to buy GlaxoSmithKline Plc's (GSK's) cancer-drug business for as much as $16 billion, form a consumer-health venture with GSK and sell its animal-health operation to Eli Lilly and Co.
ADR Shares End Mixed; Novartis, Glaxo, Philips Shares Active
... (PHG, PHIA.AE). Drug giants Novartis and GlaxoSmithKline unveiled a series of transactions worth more than $20 billion that fundamentally transform both companies, focusing Novartis's scope without significantly hitting its revenue and turning ...
Buy Stocks Like Diageo plc And GlaxoSmithKline plc To Hedge Against Labour ...
The General election is just over 12 months away, and the latest YouGov poll shows Labour with a 7% lead over the Tories. It could be time for investors to position their portfolios in anticipation of a potential Labour victory.
(Video) GlaxoSmithKline plc's Bribery Allegations
(Video) GlaxoSmithKline plc's Bribery Allegations. By Owain Bennallack - Wednesday, 16 April, 2014 | See also: GSKGSK. Tweet.
Related articles »  
GlaxoSmithKline plc's Short-Term Pain Could Be Investors' Long-Term Gain
GlaxoSmithKline's (LSE: GSK) (NYSE: GSK.US) shares have taken a beating during the past year or so, as allegations of bribery have hit the company's Chinese arm, where sales have slumped as a result.
GlaxoSmithKline plc (NYSE:GSK): The Healthcare Giant with a Difference
Dallas, Texas, 04/21/2014 (ustrademedia) - GlaxoSmithKline plc (NYSE:GSK) is global healthcare conglomerate which engages in the invention and discovery, development, manufacture and marketing of pharmaceutical products.
Is GlaxoSmithKline plc An Annuity Alternative?
Annuity giant Legal & General expects the UK annuity market to halve in size following the changes announced to pension rules in last week's Budget.
Related articles »  
GlaxoSmithKline plc (ADR) Upgraded to Buy by Panmure Gordon (GSK)
GlaxoSmithKline plc (ADR) logo GlaxoSmithKline plc (ADR) (NYSE:GSK) was upgraded by investment analysts at Panmure Gordon from a �hold� rating to a �buy� rating in a note issued to investors on Tuesday, Analyst Ratings Network reports.
New GlaxoSmithKline Diabetes Drug Needs Innovative Marketing Strategy
A diabetes drug approved last week for sale in the U.S. and Europe brings GlaxoSmithKline (GSK) into a new therapy field for the company, one that is both crowded and changing rapidly with the ageing of baby boomers and new directions in health care.
Related articles »  
GlaxoSmithKline plc (ADR) Receives �Buy� Rating from Beaufort Securities (GSK)
GlaxoSmithKline plc (ADR) (NYSE:GSK) last announced its earnings results on Wednesday, February 5th. The company reported $0.30 EPS for the quarter, meeting the Thomson Reuters consensus estimate of $0.30.